MenoBrain · Brain Health in Menopausal Women
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2025-09-01 → 2029-08-31
- Финансиране от ЕС
- 4 476 069 €
- Участници
- 20
- Схема
- HORIZON-TMA-MSCA-DN
Линиите свързват координатора с партньорите.
Накратко на български
Хормоналните промени при менопаузата и тяхното влияние върху когнитивното здраве се анализират чрез неврообразяване и изследване на чревния микробиом. Това помага за откриване на ранни признаци на мозъчни нарушения и подобряване на терапията за жените.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
With the global population of menopausal women projected to reach 1.2 billion by 2030, menopause represents a critical yet understudied period in women's health. Hormonal changes during this transition pose significant risks to brain health, cognitive function, and emotional well-being, while increasing vulnerability to age-related diseases such as Alzheimer's disease. Despite its profound societal relevance, menopause-related brain changes remain poorly understood, with limited biomarkers and evidence-based interventions available.MenoBrain aims to fill this gap by training a new generation of 15 doctoral candidates to address the pressing challenges of menopause-related brain health. The DCs will work within a multidisciplinary and international network of 18 participants (11 beneficiaries and 7 partners) spanning neuroimaging, neuropsychology, endocrinology, microbiome research and bioinformatics. MenoBrain will employ cutting-edge methods including advanced neuroimaging (MRI, DTI, PET, EEG), host-microbiome modelling, and computational BrainAGE models. This integrated approach will explore how hormonal changes associated with menopause and interventions such as menopausal hormone therapy impact cognitive health, gut-brain communication, and aging trajectories.The programme combines scientific excellence with a robust training structure to equip MenoBrain doctoral candidates with expertise in interdisciplinary and intersectoral research, advanced technologies, and transferable skills. By leveraging state-of-the-art infrastructure, MenoBrain will discover biomarkers for early detection of cognitive dysfunction, improve therapeutic strategies, and advance personalized healthcare for menopausal women.MenoBrain not only addresses a critical gap in women's health research, but also aligns with the EU's agenda to promote healthy aging, gender-specific healthcare, and fostering innovative training for the next generation of leaders in science and industry.
Оригинален текст от CORDIS (на английски).
Участници
- UNIVERSITATSKLINIKUM JENA · JenaКоординаторГермания
- ALZHEIMER EUROPE · SENNINGERBERGЛюксембург
- Bastiaanse Communication B.V. · Bosch En DuinНидерландия
- CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL · KielГермания
- DIAKONHJEMMET SYKEHUS AS · OsloНорвегия
- EBERHARD KARLS UNIVERSITAET TUEBINGEN · TuebingenГермания
- FINNADVANCE OY · HelsinkiФинландия
- FUNDACIO BARCELONABETA BRAIN RESEARCH CENTER · BarcelonaИспания
- INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE · ParisФранция
- Kerstin Minnich · WolfratshausenГермания
- Medice Arzneimittel Pütter GmbH & Co. KG · IserlohnГермания
- PARIS-LODRON-UNIVERSITAT SALZBURG · SalzburgАвстрия
- Science Matters · VlaardingenНидерландия
- Synaptikon GmbH · BerlinГермания
- UNIVERSIDAD POMPEU FABRA · BarcelonaИспания
- UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN · LübeckГермания
- UNIVERSITE DE LORRAINE · Nancy CedexФранция
- UNIVERSITEIT LEIDEN · LeidenНидерландия
- UPPSALA UNIVERSITET · UppsalaШвеция
- VILNIAUS UNIVERSITETAS · VilniusЛитва
Връзки
Данни: CORDIS, © Европейски съюз